Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Cohen

Showing results (1011-1020 of 1,023) with videos related to

Pageof 103
Sort By:
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
The Lancet. Infectious Diseases|September 5, 2024
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trialFlonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 30, 2021
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC GroupBenjamin Lacas, Alexandra Carmel, Cécile Landais, et al.
Biorxiv : the Preprint Server for Biology|June 2, 2021
Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistenceAarthi Talla, Suhas V Vasaikar, Maria P Lemos, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine primingAllan C deCamp, Martin M Corcoran, William J Fulp, et al.
Journal of Cancer Research and Clinical Oncology|August 8, 2023
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinomaKevin C Flanagan, Jon Earls, Ian Schillebeeckx, et al.
NPJ Vaccines|March 12, 2024
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine primingAllan C deCamp, Martin M Corcoran, William J Fulp, et al.
Cell|May 18, 2024
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humansWilton B Williams, S Munir Alam, Gilad Ofek, et al.
Pageof 103

Showing results (1011-1020 of 1,023) with videos related to

Sort By:
Pageof 103
The Journal of Clinical Investigation|February 14, 2023
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adultsKristen W Cohen, Andrew Fiore-Gartland, Stephen R Walsh, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy IndividualsNathan B Erdmann, Wilton B Williams, Stephen R Walsh, et al.
The Lancet. Infectious Diseases|September 5, 2024
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trialFlonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 30, 2021
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC GroupBenjamin Lacas, Alexandra Carmel, Cécile Landais, et al.
Biorxiv : the Preprint Server for Biology|June 2, 2021
Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistenceAarthi Talla, Suhas V Vasaikar, Maria P Lemos, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine primingAllan C deCamp, Martin M Corcoran, William J Fulp, et al.
Journal of Cancer Research and Clinical Oncology|August 8, 2023
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinomaKevin C Flanagan, Jon Earls, Ian Schillebeeckx, et al.
NPJ Vaccines|March 12, 2024
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine primingAllan C deCamp, Martin M Corcoran, William J Fulp, et al.
Cell|May 18, 2024
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humansWilton B Williams, S Munir Alam, Gilad Ofek, et al.
Pageof 103